ianalumabSRI-6SRI-4systemic lupus erythematosusSLENCT03656562
…ge: 17W–187W). At W28, higher proportions of patients receiving ianalumab achieved SRI-4 (70.6%), SRI-6 (50.0%), LLDAS (17.6%), DORIS (11…
2articles mentioning drugs
12drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Ianalumab ×
Ianalumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Ianalumab
2 articles · page 1 of 1deucravacitinibianalumabupadacitinibtelitaciceptBaricitinibelsubrutinibsystemic lupus erythematosus
…oral small molecule kinase inhibitors, such as upadacitinib and deucravacitinib, as potential additions to standard of care in SLE, considering…